Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-12
2011-11-15
Spector, Lorraine (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S377000, C514S018100, C558S483000
Reexamination Certificate
active
08058243
ABSTRACT:
A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.
REFERENCES:
patent: 2005/0054650 (2005-03-01), Ikonomidou
Ohgaki et al., Cancer Science, 100(12): 2235-2241, Dec. 2009.
Ahn et al., “In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog” Nature, 437(3994):894-897 (Oct. 2005).
Baker et al., “Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone” Eur J Neurosci., 20(2):575-579 (Jul. 2004).
Bao et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response” Nature, 444(7120):756-760 (Dec. 7, 2006; e-pub: Oct. 18, 2006).
Barak et al., “Reduced cancer incidence among patients with schizophrenia” Cancer, 104(12):2817-2821 (Dec. 15, 2005).
Burger et al., “Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications” Cancer, 56(5):1106-1111 (Sep. 1, 1985).
Berman et al., “Medulloblastoma growth inhibition by hedgehog pathway blockade” Science, 297(5586):1559-1561 (Aug. 30, 2002).
Carney et al., “Occurrence of cancer among people with mental health claims in an insured population” Psychosom Med., 66(5):735-743 (Sep.-Oct. 2004).
Chen et al., “Self-renewal of embryonic stem cells by a small molecule” Proc. Natl. Acad. Sci. USA., 103(46):17266-17271 (Nov. 14, 2006; e-pub Nov. 6, 2006).
Cohen et al., “Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme” Clin. Cancer Res., 11(19 pt 1):6767-6771 (Oct. 1, 2005).
Corcoran et al., “A mouse model for medulloblastoma and basal cell nevus syndrome” J. Neuro-oncol., 53(3):307-318 (Jul. 2001).
Dalton et al., “Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969-1993” Am. J. Epidemiol., 155(12):1088-1095 (Jun. 15, 2002).
Dalton et al., “Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993” Schizophr. Res., 75(2-3):315-324 (Jun. 15, 2005; e-pub: Dec. 13, 2004).
Ding et al., “A role for chemistry in stem cell biology” Nat. Biotechnol., 22(7):833-840 (Jul. 2004; e-pub: Jun. 30, 2004).
Diamandis et al., “Chemical genetics reveals a complex functional ground state of neural stem cells” Nat. Chem. Biol., 3(5):268-273 (May 2007; e-pub: Apr. 8, 2007).
Encinas et al., “Fluoxetine targets early progenitor cells in the adult brain” Proc. Natl. Acad. Sci. USA, 103(21):8233-8238 (May 23, 2006; e-pub: May 15, 2006).
Enver et al., “Loops, lineage, and leukemia” Cell, 94(1):9-12 (Jul. 10, 1998).
Galanis et al., “Chemotherapy for high-grade gliomas” Br. J. Cancer, 82(8):1371-1380 (Apr. 2000).
Galli et al., “Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma” Cancer Res., 64(19):7011-7021 (Oct. 1, 2004).
Ge et al., “GABA sets the tempo for activity-dependent adult neurogenesis” Trends Neurosci., 30(1):1-8 (Jan. 2007; e-pub: Nov. 20, 2006).
Goldacre et al., “Schizophrenia and cancer: an epidemiological study” Br. J. Psychiatry, 187:334-338 (Oct. 2005).
Gritti et al., “Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain” J. Neurosci., 19(9):3287-3297 (May 1, 1999).
Groszer et al., “PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1cell cycle entry” Proc. Natl. Acad. Sci. USA, 103(1):111-116 (Jan. 3, 2006; e-pub: Dec. 22, 2005).
Hagell et al., “Apomorphine in the treatment of Parkinson's disease” J. Neurosci. Nurs., 33(1): 21-34, 37-38 (Feb. 2001).
Hagg T., “Molecular regulation of adult CNS neurogenesis: an integrated view” Trends Neurosci., 28(11): 589-95 (Nov. 2005; e-pub: Sep. 8, 2005).
Harrist et al., “Alteration of hippocampal cell proliferation in mice lacking the β2 subunit of the neuronal nicotinic acetylcholine receptor” Synapse, 54(4):200-206 (Dec. 15, 2004).
Hemmati et al., “Cancerous stem cells can arise from pediatric brain tumors” Proc. Natl. Acad. Sci. USA, 100(25):15178-15183 (Dec. 9, 2003; e-pub: Nov. 26, 2003).
Hertz et al., “Receptor expression in primary cultures of neurons or astrocytes” Prog. Neuropsychopharmacol. Biol. Psychiatry, 8(4-6):521-527 (1984).
Hitoshi et al., “Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells” Genes Dev., 16(7):846-58 (Apr. 1, 2002).
Höglinger et al., “Dopamine depletion impairs precursor cell proliferation in Parkinson disease” Nat. Neurosci., 7(7):726-735 (Jul. 2004; e-pub Jun. 13, 2004).
Iacovelli et al., “Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas” J. Neurosci., 26(32): 8388-8397 (Aug. 9, 2006).
Kevorkov et al., “Statistical analysis of systematic errors in high-throughput screening” J. Biomol. Screen., 10(6):557-567 (Sep. 2005; e-pub Aug. 15, 2005).
Kippin et al., “Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs” J. Neurosci., 25(24):5815-5823 (Jun. 15, 2005).
Lalonde et al., “Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease” Breast, 12(4):280-282 (Aug. 2003).
Lee et al., “Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines” Cancer Cell, 9(5):391-403 (May 2006).
Lie et al., “Wnt signalling regulates adult hippocampal neurogenesis” Nature, 437:1370-1375 (Oct. 27, 2005).
Lledo et al., “Adult neurogenesis and functional plasticity in neuronal circuits” Nat. Rev. Neurosci., 7(3):179-193 (Mar. 2006).
MacDonald et al., “Identifying off-target effects and hidden phenotypes of drugs in human cells” Nat. Chem. Biol., 2(6):329-337 (Jun. 2006; e-pub: May 7, 2006).
Molofsky et al., “Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation” Nature, 425(6961): 962-967 (Oct. 30, 2003; e-pub: Oct. 22, 2003).
Nacher et al., “NMDA receptor antagonist treatment increases the production of new neurons in the aged rat hippocampus” Neurobiol. Aging, 24(2):273-284 (Mar.-Apr. 2003).
Newlands et al., “Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials” Cancer Treat Rev., 23(1):35-61 (Jan. 1997).
Lichtermann et al., “Incidence of cancer among persons with schizophrenia and their relatives” Arch. Gen. Psychiatry, 58(6):573-578 (Jun. 2001).
Phillips et al., “Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis” Cancer Cell, 9(3):157-173 (Mar. 13, 2006).
Pomeroy et al., “Prediction of central nervous system embryonal tumour outcome based on gene expression” Nature, 415(6870):436-442 (Jan. 24, 2002).
Reynolds et al., “Clonal and population analyses demonstrate that an EGF-responsive mammali
Diamandis Phedias
Dirks Peter B.
Tyers Mike
Howson & Howson LLP
HSC Research and Development Limited Partnership
MacFarlane Stacey
Mount Sinai Hospital
Spector Lorraine
LandOfFree
Method for treating a brain cancer with ifenprodil does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a brain cancer with ifenprodil, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a brain cancer with ifenprodil will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265520